Matthew K. Fust, Director at Atara Biotherapeutics, Inc. (ATRA), sold 24,572 shares at $43.57 ($1.1M) on 2018-05-14, disclosed to the SEC on 2018-05-16.
Seasonal sale ($1.1M) by Director — this insider has traded ATRA in May in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $43.57 | 12,286 | $535K | 50.0% |
| 2 | $43.57 | 12,286 | $535K | 50.0% |
| Total | $43.57 avg | 24,572 | $1.1M | 100% |
| Filing → |
| CRNX | SELL | 2024-03-22 | $2.1M | — | Filing → |
| RARE | SELL | 2024-03-11 | $859K | — | Filing → |
| CRNX | SELL | 2022-07-15 | $119K | — | Filing → |